(Q37772518)

22 August 2017

1 reference

title

New NS5B polymerase inhibitors for hepatitis C. (English)

1 reference

Florence Legrand-Abravanel

22 August 2017

1

object named as

Florence Legrand-Abravanel

0 references

Jacques Izopet

3

object named as

Jacques Izopet

1 reference

22 August 2017

Florence Legrand-Abravanel

1

1 reference

22 August 2017

Florence Nicot

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Investigational Drugs

22 August 2017

1 reference

22 August 2017

19

1 reference

22 August 2017

8

1 reference

22 August 2017

963-975

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Robust hepatitis C virus infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Nm 283, an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Mechanism of Activation of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Inhibitors of HCV NS5B polymerase. Part 2: Evaluation of the northern region of (2Z)-2-benzoylamino-3-(4-phenoxy-phenyl)-acrylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Evaluation of VCH-759 monotherapy in hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Treating hepatitis C in the prison population is cost-saving

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Analysis of the 5' Noncoding Region versus the NS5b Region in Genotyping Hepatitis C Virus Isolates from Blood Donors in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Determining hepatitis C genotype by analyzing the sequence of the NS5b region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Hepatitis C virus genotyping: interrogation of the 5' untranslated region cannot accurately distinguish genotypes 1a and 1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Hepatitis C virus genotyping based on 5' noncoding sequence analysis (Trugene).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Searching for a new anti-HCV therapy: synthesis and properties of tropolone derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

21 January 2018

Cyclophilin inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.500285

10.1517/13543784.2010.500285

21 January 2018

Identifiers

DOI

1 reference

release_ugwsmxng6ndsvdgrf4xw5doa2a

22 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ugwsmxng6ndsvdgrf4xw5doa2a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference